Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGOBSERVATIONAL

Study of Erythrocyte Parameters and Hypercoagulability in Sickle Cell Disease (SCD-TGA)

Study of Erythrocyte Parameters and Hypercoagulability in Sickle Cell Disease

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Sickle cell disease (SCD) is an inherited haemoglobinopathy disorder caused by mutations in HBB gene with amino-acid substitution on β globin chain. The consequence is synthesis of altered haemoglobin S (HbS) which polymerises in red blood cell (RBC) at deoxygenated state. SCD is associated with chronic haemolytic anaemia, vaso-occlusive crisis (VOC) leading to frequent hospitalisation. The aim of the study was to to investigate whether a combination of routine laboratory biomarkers of haemolysis could be used to predict VOC development in confirmed SCD patients.

Who May Be Eligible (Plain English)

Who May Qualify: - Sickle cell disease Who Should NOT Join This Trial: - \<18 years - pregnancy - Patient under protective guardianship or curatorship Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Sickle cell disease Exclusion Criteria: * \<18 years * pregnancy * Patient under protective guardianship or curatorship

Treatments Being Tested

BIOLOGICAL

Erythrocytic parameters and thrombin generation assay measurement

Erythrocytic parameters and thrombin generation assay measurement

Locations (1)

Rouen university Hospital
Rouen, France